FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2231530350> ?p ?o ?g. }

• W2231530350 abstract "Background: Further stratification of the 70-gene MammaPrint TM signature into ‘high’ and ‘ultra-high’ risk groups may help predict chemo-sensitivity. In I-SPY 2, patients were classified as MammaPrint High1 (MP1) or MammaPrint (ultra) High2 (MP2), with MP2 defined as MP_score AC). HER2- patients were randomized to receive N+T- >AC vs. T->AC. For HER2+ patients, neratinib was administered in place of trastuzumab (N+T->AC vs. H+T->AC). Here, we assess the performance of MP1/MP2 class as a specific biomarker of neratinib response. Methods: 115 patients in the neratinib arm and 76 concurrently randomized controls had Agilent 44K microarrays and pCR data available for analysis. We assess association between MP1/MP2 and response in the neratinib and control arms alone using Fisher’s exact test, and relative performance between arms (biomarker x treatment interaction, likelihood ratio p Results: There are 133 MP1 patients (neratinib: 74, Control: 59) and 58 MP2 patients (neratinib: 41, Control: 17), 84% (49) of which are Her2-. The distribution of pCR rates among MP1/MP2 dichotomized groups are summarized in Table 1. MP2, one of the 10 eligible signatures, did not meet the graduation threshold; and MP1/MP2 did not show a significant biomarker x treatment interaction (OR in neratinib relative to control arm = 1.25). The MP1/MP2 x treatment interaction remains non-significant after adjustment for HR and HER2 status (p=0.54). In HER2- patients receiving neratinib, 45% (15/33) of MP2 patients achieved a pCR, compared to 0% (0/17) of MP1 patients. In the HER2- controls, there is a 31% pCR rate in MP2 (5/16) vs. 18% in MP1 (7/39) patients (OR=2.14). This difference in performance between treatment arms appears significant (p=0.041). 90% of HER2+ patients are MP1, thus MP1/MP2 status x treatment interaction within the HER2+ subtype cannot be evaluated. Conclusion: Within the I-SPY 2 population as a whole, MP1/MP2 stratification does not appear to be a specific biomarker of response to neratinib relative to the control arm. The number of HER2- patients is small and precludes any definitive conclusion, but these data motivate further investigation of the biological mechanisms distinguishing MP1 from MP2 to better understand chemotherapy and/or neratanib responsiveness. Citation Format: Christina Yau, Denise M Wolf, Ashish Sanil, Jo Chien, Anne Wallace, Judy Boughey, Doug Yee, Debu Tripathy, Angela DeMichele, Rita Nanda, Steven Chiu, Claudine Isaacs, Kathy Albain, Hank Kaplan, Stacey Moulder, Rebecca Viscusi, Donald Northfelt, Kirsten Edmiston, Anthony Elias, Toncred Styblo, Barbara Haley, Lamorna Brown-Swigart, Susan Flynn, Gillian L Hirst, Meredith Buxton, Nola Hylton, Melissa Paoloni, W Fraser Symmans, Laura Esserman, Don Berry, Minetta C Liu, John W Park, Laura van 9t Veer. MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-06-29." @default.
• W2231530350 created "2016-06-24" @default.
• W2231530350 creator A5002836828 @default.
• W2231530350 creator A5005007467 @default.
• W2231530350 creator A5005537242 @default.
• W2231530350 creator A5005988887 @default.
• W2231530350 creator A5011287285 @default.
• W2231530350 creator A5013766852 @default.
• W2231530350 creator A5014634237 @default.
• W2231530350 creator A5015224704 @default.
• W2231530350 creator A5020245115 @default.
• W2231530350 creator A5020480830 @default.
• W2231530350 creator A5023674071 @default.
• W2231530350 creator A5027416339 @default.
• W2231530350 creator A5027858713 @default.
• W2231530350 creator A5033340071 @default.
• W2231530350 creator A5033544737 @default.
• W2231530350 creator A5043431861 @default.
• W2231530350 creator A5044746891 @default.
• W2231530350 creator A5046842846 @default.
• W2231530350 creator A5048468690 @default.
• W2231530350 creator A5048646563 @default.
• W2231530350 creator A5051494466 @default.
• W2231530350 creator A5059538753 @default.
• W2231530350 creator A5062190609 @default.
• W2231530350 creator A5065945123 @default.
• W2231530350 creator A5067530181 @default.
• W2231530350 creator A5069750357 @default.
• W2231530350 creator A5071176191 @default.
• W2231530350 creator A5072789687 @default.
• W2231530350 creator A5077466235 @default.
• W2231530350 creator A5078449638 @default.
• W2231530350 creator A5090318660 @default.
• W2231530350 creator A5090425501 @default.
• W2231530350 creator A5091848952 @default.
• W2231530350 date "2015-04-30" @default.
• W2231530350 modified "2023-10-17" @default.
• W2231530350 title "Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL" @default.
• W2231530350 doi "https://doi.org/10.1158/1538-7445.sabcs14-p3-06-29" @default.
• W2231530350 hasPublicationYear "2015" @default.
• W2231530350 type Work @default.
• W2231530350 sameAs 2231530350 @default.
• W2231530350 citedByCount "0" @default.
• W2231530350 crossrefType "proceedings-article" @default.
• W2231530350 hasAuthorship W2231530350A5002836828 @default.
• W2231530350 hasAuthorship W2231530350A5005007467 @default.
• W2231530350 hasAuthorship W2231530350A5005537242 @default.
• W2231530350 hasAuthorship W2231530350A5005988887 @default.
• W2231530350 hasAuthorship W2231530350A5011287285 @default.
• W2231530350 hasAuthorship W2231530350A5013766852 @default.
• W2231530350 hasAuthorship W2231530350A5014634237 @default.
• W2231530350 hasAuthorship W2231530350A5015224704 @default.
• W2231530350 hasAuthorship W2231530350A5020245115 @default.
• W2231530350 hasAuthorship W2231530350A5020480830 @default.
• W2231530350 hasAuthorship W2231530350A5023674071 @default.
• W2231530350 hasAuthorship W2231530350A5027416339 @default.
• W2231530350 hasAuthorship W2231530350A5027858713 @default.
• W2231530350 hasAuthorship W2231530350A5033340071 @default.
• W2231530350 hasAuthorship W2231530350A5033544737 @default.
• W2231530350 hasAuthorship W2231530350A5043431861 @default.
• W2231530350 hasAuthorship W2231530350A5044746891 @default.
• W2231530350 hasAuthorship W2231530350A5046842846 @default.
• W2231530350 hasAuthorship W2231530350A5048468690 @default.
• W2231530350 hasAuthorship W2231530350A5048646563 @default.
• W2231530350 hasAuthorship W2231530350A5051494466 @default.
• W2231530350 hasAuthorship W2231530350A5059538753 @default.
• W2231530350 hasAuthorship W2231530350A5062190609 @default.
• W2231530350 hasAuthorship W2231530350A5065945123 @default.
• W2231530350 hasAuthorship W2231530350A5067530181 @default.
• W2231530350 hasAuthorship W2231530350A5069750357 @default.
• W2231530350 hasAuthorship W2231530350A5071176191 @default.
• W2231530350 hasAuthorship W2231530350A5072789687 @default.
• W2231530350 hasAuthorship W2231530350A5077466235 @default.
• W2231530350 hasAuthorship W2231530350A5078449638 @default.
• W2231530350 hasAuthorship W2231530350A5090318660 @default.
• W2231530350 hasAuthorship W2231530350A5090425501 @default.
• W2231530350 hasAuthorship W2231530350A5091848952 @default.
• W2231530350 hasConcept C121608353 @default.
• W2231530350 hasConcept C126322002 @default.
• W2231530350 hasConcept C143998085 @default.
• W2231530350 hasConcept C168563851 @default.
• W2231530350 hasConcept C185592680 @default.
• W2231530350 hasConcept C2779413316 @default.
• W2231530350 hasConcept C2779786085 @default.
• W2231530350 hasConcept C2781197716 @default.
• W2231530350 hasConcept C530470458 @default.
• W2231530350 hasConcept C55493867 @default.
• W2231530350 hasConcept C71924100 @default.
• W2231530350 hasConceptScore W2231530350C121608353 @default.
• W2231530350 hasConceptScore W2231530350C126322002 @default.
• W2231530350 hasConceptScore W2231530350C143998085 @default.
• W2231530350 hasConceptScore W2231530350C168563851 @default.
• W2231530350 hasConceptScore W2231530350C185592680 @default.
• W2231530350 hasConceptScore W2231530350C2779413316 @default.
• W2231530350 hasConceptScore W2231530350C2779786085 @default.
• W2231530350 hasConceptScore W2231530350C2781197716 @default.
• W2231530350 hasConceptScore W2231530350C530470458 @default.
• W2231530350 hasConceptScore W2231530350C55493867 @default.
• W2231530350 hasConceptScore W2231530350C71924100 @default.
• W2231530350 hasLocation W22315303501 @default.

• next